Business Context and Reporting Period
Jasper Therapeutics, Inc. filed this Form 8-K on October 20, 2023, reporting an event dated October 18, 2023. The filing concerns the company’s continued listing status on the Nasdaq Capital Market and does not provide operating or financial results for a reporting period.
Key Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, or other financial metrics.
Material Changes Versus the Prior Comparable Period
- Nasdaq notified Jasper that its voting common stock had closed below the $1.00 minimum bid price requirement for 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2).
- The company received an initial 180-calendar-day compliance period ending April 15, 2024.
- There was no immediate effect on the listing or trading of the company’s common stock or public warrants. The securities continued trading on Nasdaq under the symbols JSPR and JSPRW.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Jasper can regain compliance if its common stock closes at or above $1.00 per share for at least 10 consecutive business days before April 15, 2024, subject to Nasdaq’s confirmation.
- If the deficiency is not cured, the company may qualify for an additional 180-day compliance period if it satisfies applicable market value and other initial listing requirements and provides written notice of its intention to cure, potentially through a reverse stock split.
- Nasdaq may instead determine that the company is not eligible for additional time and issue a delisting notice. The company could appeal such a determination, but there is no assurance of continued listing.
- Management intends to monitor the stock price and consider available alternatives, including a reverse stock split, if necessary.
- The company states that it cannot assure that it will regain compliance, satisfy other Nasdaq listing standards, obtain additional relief, or avoid delisting.
Investor Verification Checklist
- Verify whether Jasper regained compliance with Nasdaq’s $1.00 minimum bid price requirement by April 15, 2024.
- Check for any subsequent Nasdaq notices, delisting proceedings, appeals, or reverse stock split actions.
- Review subsequent Forms 10-K and 10-Q for cash runway, financing needs, debt, operating losses, and other factors that could affect listing compliance.
- Confirm the continued Nasdaq trading status and symbols for the common stock and public warrants.